Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc. as indicated in metadata) on May 18, 2009. The report details the entry into material definitive agreements regarding a private placement offering of securities.
Key Financial Metrics and Transaction Details
The filing discloses a capital raise transaction with the following specific terms:
- Common Stock Issued: 11,906,976 shares to two institutional investors.
- Warrants Issued to Investors: Warrants to purchase 4,167,440 shares at an exercise price of $1.31 per share.
- Warrant Terms: Exercisable immediately upon issuance for a five-year period.
- Placement Agent Fees: Rodman & Renshaw, LLC received a cash fee of $880,000 plus warrants to purchase 654,884 shares at $1.34375 per share.
- Regulatory Basis: Offered pursuant to a shelf registration statement (Form S-3) effective June 27, 2008.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. Those figures are not contained in this specific 8-K report.
Material Changes
The primary material change is the execution of Securities Purchase Agreements on May 18, 2009, resulting in the issuance of significant equity and warrant instruments to institutional investors. This represents a dilution event and a change in the company's capital structure.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation by reference of the full Securities Purchase Agreement and Warrant forms. The transaction was executed on a "best efforts" basis by the placement agent.
Investor Verification Checklist
- Verify the total gross proceeds raised from the sale of 11,906,976 shares (price per share is not explicitly stated in the text, though warrant prices are listed).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for covenants or restrictions.
- Confirm the impact of the new shares and warrants on the fully diluted share count.
- Check the press release (Exhibit 99.1) for additional context on the use of proceeds.